{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T04:22:42Z","timestamp":1743740562376,"version":"3.40.3"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1726","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>Palopegteriparatide (Yorvipath \u2013 Ascendis), a parathyroid hormone (PTH) 1-34 analog, has been approved by the FDA for treatment of hypoparathyroidism in adults. The parathyroid hormone analog teriparatide (Forteo, and others), which is approved for treatment of postmenopausal osteoporosis, has been used offlabel for treatment of hypoparathyroidism.<\/jats:p>","DOI":"10.58347\/tml.2025.1726c","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T18:19:41Z","timestamp":1743704381000},"page":"60-62","source":"Crossref","is-referenced-by-count":0,"title":["Palopegteriparatide (Yorvipath) for Hypoparathyroidism"],"prefix":"10.58347","volume":"67","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2025,4,14]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T18:19:41Z","timestamp":1743704381000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1726c"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":0,"journal-issue":{"issue":"1726","published-online":{"date-parts":[[2025,4,14]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2025.1726c","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]}}}